Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa's prodrug chemistry for oral beta-lactamase inhibitors

April 1, 2019 1:15 PM UTC

Arixa has made an IV antibiotic oral with prodrug chemistry.

Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with β-lactam antibiotics to treat Gram-negative infections. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Arixa Pharmaceuticals Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)